United States - English - NLM (National Library of Medicine)

physicians total care, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 0.3 mg - epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (type i) including anaphylaxis to stinging insects (e.g. order hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. selection of the appropriate dosage strength is determined according to patient body weight (see dosage and administration section). such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, w

United States - English - NLM (National Library of Medicine)

septodont inc. - prilocaine hydrochloride (unii: mjw015baph) (prilocaine - unii:046o35d44r), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - prilocaine hydrochloride 40 mg in 1 ml - prilocaine hydrochloride 4% with epinephrine 1:200,000 injection is indicated for the production of local anesthesia in dentistry by nerve block or infiltration techniques. only accepted procedures for these techniques as described in standard textbooks are recommended. prilocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type and in those rare patients with congenital or idiopathic methemoglobinemia.

United States - English - NLM (National Library of Medicine)

bpi labs, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 1 mg in 1 ml - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. induction and maintenance of mydriasis during intraocular surgery. none. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. epinephrine crosses the placenta. e

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 1 mg in 1 ml - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. emergency treatment of allergic reactions (type i), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. the signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue. induction and maintenance of mydriasis during intraocular surgery. none. risk summary prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, does not identify a d

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 0.1 mg in 1 ml - epinephrine injection, usp is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (a-v) heart block with syncopal seizures (stokes-adams syndrome). in acute attacks of ventricular standstill, physical measures should be applied first. when external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. epinephrine is contraindicated in patients with known hypersensitivity to sympathomimetic amines, in patients with angle closure glaucoma, and patients in shock (nonanaphylactic). it should not be used in patients anesthetiz

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine 0.1 mg in 1 ml - epinephrine epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (av) heart block with syncopal seizures (stokes-adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. in cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. epinephrine should not be used in the presence of car

United States - English - NLM (National Library of Medicine)

septodont, inc. - articaine hydrochloride (unii: qs9014q792) (articaine - unii:d3sq406g9x), epinephrine bitartrate (unii: 30q7ki53ak) (epinephrine - unii:ykh834o4bh) - zorcaine®  is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age or older. zorcaine is contraindicated in patients who are hypersensitive to products containing sulfites. products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people [see warnings and precautions (5.5)]. teratogenic effects - pregnancy category c. there are no adequate and well-controlled studies in pregnant women with zorcaine. articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (mrhd). zorcaine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the mrhd based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. in contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the mrhd based on body surface area). in pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the mrhd based on body surface area) increased the number of stillbirths and adversely affected passive avoidance, a measure of learning, in pups. this dose also produced severe maternal toxicity in some animals. a dose of 40 mg/kg (approximately equal to the mrhd on a mg/m2 basis) did not produce these effects. a similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring. it is not known whether zorcaine is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when zorcaine is administered to a nursing woman. when using zorcaine, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half life) following an injection of zorcaine (to minimize infant ingestion) and then resume breastfeeding. safety and effectiveness of zorcaine in pediatric patients below the age of 4 years have not been established. safety of doses greater than 7 mg/kg (0.175 ml/kg) in pediatric patients has not been established. the safety and effectiveness of zorcaine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered articaine hydrochloride 4% and epinephrine 1:100,000 injections. fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 to 5.1 ml) for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 to 3.9 ml) for complex dental procedures. approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see dosage and administration (2.2)]. in clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received zorcaine containing epinephrine 1:100,000. among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 to 11.9 ml) were administered to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 to 6.8 ml) were administered to 19 patients for complex procedures. among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 to 11.9 ml) were administered to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 to 5.1 ml) were administered to 4 patients for complex procedures. approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections. no overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. no studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4% and epinephrine 1:100,000 injection in patients with renal or hepatic impairment [see warnings and precautions (5.2)].

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fkp "armavirskaya biofabrika" - articaine (articaine hydrochloride), epinephrine (epinephrine hydrotartrate) - solution for injection - 40mg/ml+ 0.01mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fkp "armavirskaya biofabrika" - articaine (articaine hydrochloride), epinephrine (epinephrine hydrotartrate) - solution for injection - 40mg/ml+ 0.01mg/ml

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pierrel s.p.a. - epinephrine hydrochloride 12 µg/ml - eq. epinephrine 10 µg/ml; articaine hydrochloride 40 mg/ml - solution for injection - 40 mg/ml - 10 µg/ml - epinephrine hydrochloride 12 µg/ml; articaine hydrochloride 40 mg/ml - articaine, combinations